de
Ulrich Jaehde
© Heiko Specht
Prof. Dr. Ulrich Jaehde

Webseite

Zugehörigkeiten
  • Pharmazeutisches Institut
Forschungsschwerpunkte
  • pharmacometrics
  • medication safety
  • anti-cancer drug treatment
Our research focuses on the development and application of pharmacometric models for anticancer drugs to optimise drug therapy for better patient outcomes. The models aim at integrating pharmacokinetic (PK) disposition, pharmacodynamic (PD) biomarkers and clinical outcome enabling simulations of unknown situations (e.g. new dosage regimens). Moreover, physiologically based pharmacokinetic (PBPK) models are developed for special populations such as elderly patients. Another focus is the development of risk models predicting adverse drug reactions in various clinical settings in order to identify patients in particular need of specific measures to enhance medication safety. In an interdisciplinary approach, our group contributes to the development of a health IT infrastructure capable of supporting IT-based medication safety for patients with polymedication („Medical Informatics Initiative Germany“).
Ausgewählte Publikationen

Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Hilger RA, Roessler M, Kloft C, Henrich A, Moritz B, Miller MC, Salamone SJ, Jaehde U (2016) Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 27:1895-902.

Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U (2016) Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet 55:1573-1589.

Hagelstein V, Ortland I, Wilmer A, Mitchell SA, Jaehde U (2016) Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™). Ann Oncol 27:2294-2299.

Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, Sörgel F, Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney LA, Guchelaar HJ, Jaehde U (2017) Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer. CPT Pharmacometrics Syst Pharmacol 6:604-613.

Ulrich Jaehde
© Heiko Specht
Prof. Dr. Ulrich Jaehde

Webseite

-